FLGT vs. VCYT, LFST, ARDT, ADUS, PGNY, PACS, WGS, NHC, TDOC, and GRAL
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Veracyte (VCYT), LifeStance Health Group (LFST), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), PACS Group (PACS), GeneDx (WGS), National HealthCare (NHC), Teladoc Health (TDOC), and Grail (GRAL). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs.
Veracyte (NASDAQ:VCYT) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
Veracyte received 207 more outperform votes than Fulgent Genetics when rated by MarketBeat users. Likewise, 73.14% of users gave Veracyte an outperform vote while only 59.76% of users gave Fulgent Genetics an outperform vote.
Veracyte presently has a consensus price target of $40.90, indicating a potential upside of 48.59%. Fulgent Genetics has a consensus price target of $24.00, indicating a potential upside of 19.17%. Given Veracyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Veracyte is more favorable than Fulgent Genetics.
Veracyte has a net margin of -2.18% compared to Fulgent Genetics' net margin of -59.39%. Veracyte's return on equity of 3.02% beat Fulgent Genetics' return on equity.
Veracyte has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
In the previous week, Veracyte had 9 more articles in the media than Fulgent Genetics. MarketBeat recorded 16 mentions for Veracyte and 7 mentions for Fulgent Genetics. Veracyte's average media sentiment score of 1.30 beat Fulgent Genetics' score of 1.07 indicating that Veracyte is being referred to more favorably in the media.
Veracyte has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
48.1% of Fulgent Genetics shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Veracyte beats Fulgent Genetics on 15 of the 18 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy FLGT Stock Free FLGT Stock Alerts